Loss of HIF1A from pancreatic cancer cells increases expression of PPP1R1B and degradation of p53 to promote invasion and metastasis
Background & Aims Pancreatic ductal adenocarcinomas (PDACs) are hypovascular,
resulting in the up-regulation of hypoxia inducible factor 1 alpha (HIF1A), which promotes the …
resulting in the up-regulation of hypoxia inducible factor 1 alpha (HIF1A), which promotes the …
Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre …
…, T Karashima, K Masui, F Fukuta, K Tashiro… - Cancer Immunology …, 2022 - Springer
Neutrophil-to-lymphocyte ratio (NLR) was reported to be associated with prognosis of urothelial
cancer (UC) patients receiving systemic chemotherapy or immunotherapy. However, it …
cancer (UC) patients receiving systemic chemotherapy or immunotherapy. However, it …
Impact of the objective response to and number of cycles of platinum‐based first‐line chemotherapy for metastatic urothelial carcinoma on overall survival of patients …
…, R Kurahashi, Y Ozaki, Y Tashiro… - … Journal of Urology, 2021 - Wiley Online Library
Objectives To investigate the impact of the number of cycles and objective response to
chemotherapy on overall survival in patients with metastatic urothelial carcinoma treated with …
chemotherapy on overall survival in patients with metastatic urothelial carcinoma treated with …
[HTML][HTML] Risk factors for perioperative hemodynamic instability in pheochromocytoma: a systematic review and meta-analysis
…, K Iwatani, K Takahashi, K Ito, K Tashiro… - Journal of clinical …, 2021 - mdpi.com
Objective: To evaluate the risk factors of perioperative hemodynamic instability in
pheochromocytoma, we conducted a systematic search of the literature using the Preferred …
pheochromocytoma, we conducted a systematic search of the literature using the Preferred …
Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis
…, H Araki, R Kurahashi, Y Ozaki, Y Tashiro… - BJU …, 2022 - Wiley Online Library
Objectives To assess the impact of histological variants on survival and response to treatment
with pembrolizumab in patients with chemo‐resistant urothelial carcinoma (UC). Patients …
with pembrolizumab in patients with chemo‐resistant urothelial carcinoma (UC). Patients …
Radiotherapy plus androgen deprivation therapy for prostate‐specific antigen persistence in lymph node–positive prostate cancer
The treatment for lymph node involvement (LNI) after radical prostatectomy (RP) has not
been established. This study aimed to reveal the outcomes of various management strategies …
been established. This study aimed to reveal the outcomes of various management strategies …
Prognostication in lymph node-positive prostate cancer with no PSA persistence after radical prostatectomy
…, M Miyake, M Tsutsumi, Y Yamamoto, K Tashiro… - Annals of Surgical …, 2024 - Springer
Background This study aimed to create a prognostic model to predict disease recurrence
among patients with lymph node involvement but no prostate-specific antigen (PSA) …
among patients with lymph node involvement but no prostate-specific antigen (PSA) …
The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and …
…, F Urabe, K Iwatani, H Suzuki, Y Imai, K Tashiro… - International Journal of …, 2023 - Springer
Background Although the optimal management of locally advanced prostate cancer (PCa)
remains unclear, local definitive therapy, thus combined radiotherapy and androgen …
remains unclear, local definitive therapy, thus combined radiotherapy and androgen …
Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy
…, F Urabe, K Iwatani, M Nakazono, K Tashiro… - International Journal of …, 2023 - Springer
Background Although brachytherapy is a standard treatment option for patients with high-risk
prostate cancer, only a few studies have compared low-dose-rate brachytherapy (LDR-BT) …
prostate cancer, only a few studies have compared low-dose-rate brachytherapy (LDR-BT) …
How long is long enough to secure disease control after low-dose-rate brachytherapy in combination with other modalities in intermediate-risk, localized prostate …
Purpose Previous studies have demonstrated excellent overall outcomes in patients who
underwent low-dose-rate brachytherapy (LDR-BT) in intermediate-risk, localized prostate …
underwent low-dose-rate brachytherapy (LDR-BT) in intermediate-risk, localized prostate …